Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Sucralfate showed no clear difference in oral mucositis (any severity) compared with placebo/usual care (moderate certainty).
1 finding from 1 review
Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Sucralfate probably leads to lower oral mucositis (severe) compared with placebo/usual care (moderate certainty).
1 finding from 1 review
Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Sucralfate showed no clear difference in oral mucositis (moderate to severe) compared with placebo/usual care; GRADE not reported.
1 finding from 1 review
RR 0.75 [0.54, 1.04]
4 studies
GRADE not reported
Mucositis eradicated · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Sucralfate showed no clear difference in mucositis eradicated compared with placebo; GRADE not reported.
1 finding from 1 review
Improvement in mucositis · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Sucralfate showed no clear difference in improvement in mucositis compared with placebo; GRADE not reported.
1 finding from 1 review
Time to heal mucositis (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Sucralfate showed no clear difference in time to heal mucositis (days) compared with salt and soda mouthwash; GRADE not reported.
1 finding from 1 review
Average pain scores (0-100 VAS) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Sucralfate showed no clear difference in average pain scores (0-100 VAS) compared with salt and soda mouthwash; GRADE not reported.
1 finding from 1 review
Duration of episodes · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in mean duration of episodes compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Time to complete healing · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in healing time compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Number of episodes · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in number of episodes compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Pain (0-3 scale) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in pain (0-3 scale) compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Number of painful days · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in number of painful days compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Episode frequency associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in frequency of oral ulcers compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Episode frequency associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
Studies not reported
GRADE not reported
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
Studies not reported
GRADE not reported
Pain associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
Studies not reported
GRADE not reported
Episode duration associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
Studies not reported
GRADE not reported
Interruptions to cancer treatment · Adults receiving radiotherapy to the head and neck
Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash showed no clear difference in interruptions to cancer treatment compared with sucralfate mouthwash; GRADE not reported.
1 finding from 1 review
Normalcy of diet (percutaneous endoscopic gastrostomy) · Adults receiving radiotherapy to the head and neck
Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash showed no clear difference in normalcy of diet (percutaneous endoscopic gastrostomy) compared with sucralfate mouthwash; GRADE not reported.
1 finding from 1 review
Oral mucositis (severe) · Adults receiving radiotherapy to the head and neck
Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash showed no clear difference in oral mucositis (severe) compared with sucralfate mouthwash; GRADE not reported.
1 finding from 1 review